Drug-related bullous fixed pigmented erythema related to the use of ivermectin in a patient with SARS-Cov2 pneumonia: Case Report

• Autores: Aguilar-Urbina, Edi William, Plasencia-Meza, Carlos, Chávez-Rimarachin, Manuel, Aquino-Salverredy, Regina, Velásquez-Ojeda, Anghelo
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/1280
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/1280
• Nivel de acceso: acceso abierto
• Materia: Eritema fijo pigmentado ampolloso; toxicodermia; eritema pigmentario medicamentoso; Bullous pigmented fixed erythema; toxicoderma; drug erythema pigmentation

Background: Bullous fixed pigmented erythema is a potentially serious form of toxicoderma. It is characterized by the appearance of cutaneous and / or mucosal lesions, single or multiple, which can appear in any area, after the administration of a drug or other substance. A 73-year-old man is presented with a diagnosis of bullous fixed pigmented erythema secondary to the ingestion of ivermectin. It is necessary for the physician to recognize the adverse effects of self-medication with ivermectin against SARS CoV-2, to make an early diagnosis and initiate timely treatment.